Chen J T, Okamoto T, Hasumi K, Masubuchi K
Toray Research Center Inc., Biological Science Dept.
Gan To Kagaku Ryoho. 1989 Jan;16(1):67-71.
The combined effect of cisplatin (CDDP) and aclarubicin (ACR) which was reported to inhibit the repair of the sublethal and the potentially lethal X-ray damages, was studied with human lymphocytes. The cell kinetics during administration of CDDP or ACR were analysed by flow cytometry. CDDP at the concentration of 0.5 microgram/ml had no effect on the cell progression. ACR blocked the cell progression at G1 period at the concentrations of 100 and 200 ng/ml, but the number of dead cells was not increased. When these two agents were combined, the number of dead cells increased more than 10 times compared to that of ACR alone. In conclusion, it was found that the combination of CDDP with ACR had a synergistic effect.
据报道,顺铂(CDDP)和阿克拉霉素(ACR)联合使用可抑制亚致死性和潜在致死性X射线损伤的修复,本研究以人淋巴细胞为对象对此进行了探讨。通过流式细胞术分析了CDDP或ACR给药期间的细胞动力学。浓度为0.5微克/毫升的CDDP对细胞进程无影响。浓度为100和200纳克/毫升的ACR在G1期阻断细胞进程,但死亡细胞数量未增加。当这两种药物联合使用时,死亡细胞数量比单独使用ACR时增加了10倍以上。总之,发现CDDP与ACR联合使用具有协同作用。